Cargando…

Patient Registries in Idiopathic Pulmonary Fibrosis

Over the past decade, several large registries of patients with idiopathic pulmonary fibrosis (IPF) have been established. These registries are collecting a wealth of longitudinal data on thousands of patients with this rare disease. The data collected in these registries will be complementary to da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Culver, Daniel A., Behr, Jürgen, Belperio, John A., Corte, Tamera J., de Andrade, Joao A., Flaherty, Kevin R., Gulati, Mridu, Huie, Tristan J., Lancaster, Lisa H., Roman, Jesse, Ryerson, Christopher J., Kim, Hyun J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2019
Materias:	Concise Clinical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635784/ https://www.ncbi.nlm.nih.gov/pubmed/31034241 http://dx.doi.org/10.1164/rccm.201902-0431CI

Ejemplares similares

Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry
por: Case, Amy Hajari, et al.
Publicado: (2020)

Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
por: Rahaghi, Franck, et al.
Publicado: (2021)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

Importance of Occupational Exposure Data: A National Idiopathic Pulmonary Fibrosis Registry Perspective
por: Teoh, Alan K. Y., et al.
Publicado: (2020)

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
por: Snyder, Laurie, et al.
Publicado: (2019)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Idiopathic pulmonary fibrosis: the radiologist’s role in making the diagnosis
por: Mohning, Michael P., et al.
Publicado: (2019)

Managing comorbidities in idiopathic pulmonary fibrosis
por: Fulton, Blair G, et al.
Publicado: (2015)

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
por: Jo, Helen E., et al.
Publicado: (2018)

Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry
por: Conway, Richard, et al.
Publicado: (2021)

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
por: Todd, Jamie L., et al.
Publicado: (2020)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Reply to Nett et al.: Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries
por: Culver, Daniel A., et al.
Publicado: (2020)

Idiopathic/Simple Onycholysis: Response to Combination Topical Therapy
por: Grover, Chander, et al.
Publicado: (2022)

Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study
por: Parker, Matthew J S, et al.
Publicado: (2018)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
por: Kim, Hyun J., et al.
Publicado: (2022)

Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
por: Zheng, Qiang, et al.
Publicado: (2022)

Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis
por: Cox, Ingrid A., et al.
Publicado: (2020)

Losartan ameliorates TGF-β1–induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies
por: Kim, Michael D., et al.
Publicado: (2022)

Method for detection of respiratory viruses in the sputa of patients with cystic fibrosis
por: Punch, G., et al.
Publicado: (2004)

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2022)

The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
por: Cox, Ingrid A., et al.
Publicado: (2022)

Evaluation of a hybrid antimicrobial restriction process at a large academic medical center
por: Smith, Jesse D., et al.
Publicado: (2021)

Content Analysis of Idiopathic Pulmonary Fibrosis-related Information on Twitter
por: Ong, Shaun, et al.
Publicado: (2022)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease
por: Ryerson, Christopher J., et al.
Publicado: (2021)

There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)
por: Nambiar, Shabarinath, et al.
Publicado: (2021)

Defining new clinically derived criteria for high disease activity in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study
por: Backström, Maria, et al.
Publicado: (2018)

Guidelines or guidance for better idiopathic pulmonary fibrosis management?
por: Behr, Jürgen
Publicado: (2016)

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
por: de Andrade, Joao A., et al.
Publicado: (2022)

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
por: Noth, Imre, et al.
Publicado: (2021)

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
por: Bonella, Francesco, et al.
Publicado: (2023)

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry
por: Ryerson, Christopher J., et al.
Publicado: (2016)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis
por: Fisher, J. H., et al.
Publicado: (2019)

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
por: Holtze, Colin H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bphk1duk4r1ict1ipfkgvjvbc7